Safety and effectiveness of insulin aspart in type 2 diabetic patients: Results from the ASEAN cohort of the A1chieve study

Diabetes Research and Clinical Practice

Volumn 100, Issue SUPPL.1, 2013, Pages

  Bebakar, Wan Mohamad Wan ^a   Lim Abrahan, Mary Anne ^b   Jain, Ananá B ^c   Seah, Darren ^d   Soewondo, Pradana ^e  

^a SCHOOL OF HEALTH SCIENCES   (Malaysia)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c NOVO NORDISK A S   (Denmark)

^d NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^e UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

A1chieve; ASEAN; Insulin aspart; Non interventional study; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN ASPART; INSULIN DETEMIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASIA; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ASIA, SOUTHEASTERN; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84877107844     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/S0168-8227(13)70005-6     Document Type: Article

References (18)

1. Whiting DR, Guariguata L, Weil C, Shaw J IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94(3):311-321.
2. International Diabetes Federation IDF Diabetes Atlas 2011, International Diabetes Federation, Brussels, Belgium. 5th edn.
3. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
4. Choi JH, Park CY, Cha BS, Kim IJ, Park TS, Park JY, et al. Perception of clinicians and diabetic patients on the importance of postprandial glucose control and diabetes education status: a cross sectional survey. Diabetes Metab J 2012, 36(2):120-127.
5. Sourij H, Schmoelzer I, de Campo A, Tripolt NJ, Stojakovic T, Scharnagl H, et al. Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes. Eur J Endocrinol 2011, 165(2):269-274.
6. Lindholm A, Jacobsen LV Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001, 40(9):641-659.
7. Chapman TM, Noble S, Goa KL Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002, 62(13):1945-1981.
8. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000, 37(1):41-46.
9. Reynolds NA, Wagstaff AJ Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004, 64(17):1957-1974.
10. Mayfield JA, White RD Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004, 70(3):489-500.
11. Krumholz HM Outcomes research: generating evidence for best practice and policies. Circulation 2008, 118(3):309-318.
12. Paz-Pacheco E Diabetes Clinical Practice Guidelines (CPGs) for the ASEAN region: Country initiatives for collectively enhanced diabetes care in the region. JAFES 2011, 26(1):36-37.
13. 1chieve study. Diabetes Res Clin Pract 2011, 94:352-363.
14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(6):1577-1596.
15. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, IMPROVE Study Group Expert Panel, et al. The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008, 62(11):1809-1819.
16. UKPDS Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
17. Turner RC, Cull CA, Frighi V, Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281(21):2005-2012.
18. Yki-Järvinen H Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24(4):758-767.